Evidence map›Paper›PMID 41233807›Full record

ArticleJournal of translational medicine2025

TRIML2 promotes malignant progression of head and neck squamous cell carcinoma via canonical Wnt signaling and tumor immune escape.

Xi Luo, Yang Zhang, Yingjian Wang, Huike Wang, Dao Xin, Lulu Guan, Zhe Wang, Pei Wang, Feng Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Integrative multi-omics reveals the POSTNFrontiers in immunology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Xi Luo *Department of Oncology, The First Affiliated Hospital of Zhengzhou University, No. 1 Jianshe East Road, Zhengzhou, 450000, China.
Yang Zhang *The First Clinical Medical College of Zhengzhou University, Zhengzhou, China.
Yingjian Wang *The First Clinical Medical College of Zhengzhou University, Zhengzhou, China.
Huike WangDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, No. 1 Jianshe East Road, Zhengzhou, 450000, China.
Dao XinDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, No. 1 Jianshe East Road, Zhengzhou, 450000, China.
Lulu GuanDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, No. 1 Jianshe East Road, Zhengzhou, 450000, China.
Zhe WangThe First Clinical Medical College of Zhengzhou University, Zhengzhou, China.
Pei WangDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, No. 1 Jianshe East Road, Zhengzhou, 450000, China.
Feng WangDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, No. 1 Jianshe East Road, Zhengzhou, 450000, China. zzuwangfeng@zzu.edu.cn.ORCID 0000-0003-3335-5943

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe roles and underlying mechanisms of tripartite motif family like 2 (TRIML2) in tumors, including head and neck squamous cell carcinoma (HNSC), remain poorly characterized. This study aimed to comprehensively characterize the significance of TRIML2 in HNSC using multi-omics analyses and experimental validation.

methodsDifferentially expressed genes in HNSC were screened from TCGA and GEO datasets, and TRIML2 was identified as a hub gene for further investigation. Its expression patterns, diagnostic and prognostic value, associations with clinicopathological features, drug sensitivity, and immune infiltration were systematically analyzed. Gene set enrichment analysis (GSEA) and protein–protein interaction (PPI) network analysis were performed to explore TRIML2-related signaling pathways. The biological function and molecular mechanisms of TRIML2 were further validated through in vitro and in vivo experiments.

resultsTRIML2 was significantly upregulated in HNSC, and correlated with worse overall survival (OS), progression-free survival (PFS) and disease-free survival (DFS). High TRIML2 expression was associated with advanced tumor stage, distant metastasis, increased infiltration of immunosuppressive cells, elevated expression of immunosuppressive molecules, and activation of multiple oncogenic pathways. Silencing TRIML2 inhibited cell proliferation, migration, invasion, epithelial-mesenchymal transition (EMT), canonical Wnt pathway activity, immunosuppressive molecule expression and tumor growth in vitro and in vivo, whereas TRIML2 overexpression produced the opposite effects.

conclusionsTRIML2 promotes malignant progression of HNSC by activating the canonical Wnt pathway and facilitating tumor immune escape. TRIML2 represents a promising biomarker for diagnosis, immunotherapy, and prognosis in HNSC.

Indexed as

Disease ProgressionHead and Neck NeoplasmsSquamous Cell Carcinoma of Head and NeckTumor EscapeWnt Signaling PathwayAnimalsCell Line, TumorCell MovementCell ProliferationEpithelial-Mesenchymal TransitionFemaleGene Expression Regulation, NeoplasticHumansMalePrognosisProtein Interaction MapsCanonical Wnt signaling pathwayEpithelial-mesenchymal transitionHead and neck squamous cell carcinomaImmune escapePrognosisTRIML2

Identifiers

PMID41233807
PMCPMC12613471

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.